Lilly raises 2026 revenue outlook after third-quarter sales reach $24.4 billion

Indianapolis-based Eli Lilly reported $24.4 billion in worldwide third-quarter revenue on Oct. 29, up 39% from the same period a year earlier. The company’s quarterly results put 2026 sales on a higher track: it now projects $91 billion to $92 billion in full-year revenue, compared with its previous range of $85 billion to $87 billion.

Lilly attributed the revenue increase largely to greater sales volume for its medicines, including Mounjaro and Zepbound. Its release said volume rose 53% while realized prices fell 15%. Reported earnings per share were $7.22, compared with $6.21 a year earlier. The company also reported $4.2 billion in third-quarter research and development spending, up 23%.

The results matter locally because Lilly is headquartered in Indianapolis and is one of Indiana’s largest companies. They describe global operations, however; the quarterly figures alone do not establish a change in Indiana employment or a new local facility. Lilly’s Oct. 29 earnings release supplies the figures, with its earnings-call materials available to investors.

Report a correction · Editorial standards · Our source directory

BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.

SOURCE STATUS: One-source report; independent confirmation pending.